癌症是广泛分类的疾病,其可由于未知原因的异常细胞增殖而影响任何器官或身体组织。许多现有的化疗药物具有高毒性并且几乎没有选择性。此外,它们导致药物抵抗的发展。因此,开发具有最小副作用和良好选择性的定制化疗药物对于癌症治疗至关重要。2-(1H)-喹唑啉酮是重要的支架材料之一,抗癌活性是该类材料中突出的生物学活性之一。在这里,我们报告了新型的富含酰胺的2-(1H)-喹唑啉酮衍生物(7a-j)及其凋亡活性,并借助MTT分析方法对四种人类癌细胞系:PC3(前列腺癌),DU-145(前列腺癌),A549(肺癌),和MCF7(乳腺癌)。与依托泊苷相比,每种合成的测试化合物(7a-j)表现出中等至优异的活性。新的酰胺衍生物(7a-j)的IC50值从0.07±0.0061μM变化到10.8±0.69μM。而阳性对照,依托泊苷,表现出1.97±0.45μM至3.08±0.135μM的范围。在新的酰胺衍生物(7a-j)中,特别是,7i和7j显示针对MCF7的强凋亡活性;7h显示针对PC3,7g显示针对DU-145。测试化合物(7a-j)与EGFR酪氨酸激酶结构域(PDBID:1M17)蛋白的分子对接研究提供了每种测试化合物(7a-j)的显著对接评分(-9.00至-9.67kcal/mol)。此外,DFT研究和MD模拟验证了分子对接的预测。根据ADME分析的结果,对于所有测试化合物,人的口服吸收预计高于85%。
Cancer is a broad classification of diseases that can affect any organ or body tissue due to aberrant cellular proliferation for unknown reasons. Many present chemotherapeutic drugs are highly toxic and have little selectivity. Additionally, they lead to the development of medication resistance. Therefore, developing tailored chemotherapeutic drugs with minimal side effects and good selectivity is crucial for cancer treatment. 2-(1H)-Quinazolinone is one of the vital scaffold and anticancer activity is one of the prominent biological activities of this class. Here we report the novel set of amide-enriched 2-(1H)-quinazolinone derivatives (7a-j) and their apoptotic activity with the help of MTT assay method against four human cancer cell lines: PC3 (prostate cancer), DU-145 (prostate cancer), A549 (lung cancer), and MCF7 (breast cancer). When compared to etoposide, every synthetic test compound (7a-j) exhibited moderate to excellent activity. The IC50 values of the new amide derivatives (7a-j) varied from 0.07 ± 0.0061 μM to 10.8 ± 0.69 μM. While the positive control, etoposide, exhibited 1.97 ± 0.45 μM to 3.08 ± 0.135 μM range. Among the novel amide derivatives (7a-j), in particular, 7i and 7j showed strong apoptotic activity against MCF7; 7h showed against PC3, and 7g showed against DU-145. Molecular docking studies of test compounds (7a-j) with the EGFR tyrosine kinase domain (PDB ID: 1M17) protein provided the significant docking scores for each test compound (7a-j) (-9.00 to -9.67 kcal/mol). Additionally, DFT investigations and MD simulations validated the predictions of molecular docking. According to the findings of the ADME analysis, oral absorption by humans is anticipated to be higher than 85 % for all test compounds.